Exane Derivatives Dbv Technologies S.A. Transaction History

Exane Derivatives

$157 Million
Q2 2022

A detailed history of Exane Derivatives transactions in Dbv Technologies S.A. stock. As of the latest transaction made, Exane Derivatives holds 101 shares of DBVT stock, worth $307. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101

Previous 101 -0.0%

Holding current value

$307

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 30, 2021	SELL	$2.75 - $6.57 $5,222 - $12,476	-1,899 Reduced 94.95%	101 $0
Q4 2020 Jan 27, 2021	BUY	$1.38 - $3.01 $1,606 - $3,503	1,164 Added 139.23%	2,000 $5,000
Q3 2020 Oct 06, 2020	SELL	$1.58 - $4.77 $19,219 - $58,022	-12,164 Reduced 93.57%	836 $1,000
Q1 2020 Apr 17, 2020	BUY	$2.33 - $12.98 $30,290 - $168,740	13,000 New	13,000 $50,000

Others Institutions Holding DBVT

# of Institutions

Shares Held

3.2K

Call Options Held

Put Options Held

Cutler Group LP

3.1K
Shares

$9,424
0.0% of portfolio

View Full List

About DBV Technologies S.A.

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $571M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

More about DBVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Account

Exane Derivatives Dbv Technologies S.A. Transaction History